Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will ...
Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment ...
Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
NEW YORK, NY / ACCESSNEWSWIRE / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
FiercePharma6d
JPM25: Regeneron CEO says it needs more 'arrows in its quiver' as Eylea HD sales fall short
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.
FierceBiotech7d
JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project
Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...
BioSpace6d
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...